<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247920</url>
  </required_header>
  <id_info>
    <org_study_id>RAIN</org_study_id>
    <nct_id>NCT03247920</nct_id>
  </id_info>
  <brief_title>Reduction of Intravenous Antibiotics In Neonates</brief_title>
  <acronym>RAIN</acronym>
  <official_title>Intravenous to Oral Antibiotic Switch Therapy for Probable Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Franciscus Gasthuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Franciscus Gasthuis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled open-label non-inferiority trial comparing complete intravenous&#xD;
      antibiotic treatment with a short iv. course followed by oral antibiotics in neonates (0-28&#xD;
      days) with probable bacterial infection.&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      - Bacterial re-infection within 28 days after finishing of antibacterial therapy.&#xD;
&#xD;
      Secondary outcome(s):&#xD;
&#xD;
        -  Pharmacokinetic profile of oral amoxicillin/clavulanic acid&#xD;
&#xD;
        -  Quality of life&#xD;
&#xD;
        -  Cost-effectiveness&#xD;
&#xD;
        -  Alterations in gut microbiome&#xD;
&#xD;
        -  Use of molecular techniques for better detection of bacterial pathogens&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonates have a high antibiotic consumption because of their susceptibility for bacterial&#xD;
      infections. Since the early diagnosis of bacterial infection in neonates is difficult,&#xD;
      intravenous broad-spectrum antimicrobial therapy is usually started promptly after subtle&#xD;
      symptoms. The majority of neonates become asymptomatic shortly after initiation; when&#xD;
      infection is probable or proven by elevated inflammatory markers and/or a positive blood&#xD;
      culture, intravenous antibiotics are administered for at least 7 days.&#xD;
&#xD;
      However, for neonates blood culture has a limited sensitivity. Therefore, the majority of&#xD;
      neonates with probable infection are treated for a prolonged time with intravenous&#xD;
      broad-spectrum antimicrobial therapy. In older children, intravenous antibiotics are often&#xD;
      changed to oral antibiotics after cessation of symptoms and decreasing inflammatory&#xD;
      parameters. This is not yet widely practised in neonates because of uncertainties in&#xD;
      pharmacokinetics. Two explorative small studies from France and Italy into neonatal&#xD;
      antibiotic switch therapy suggest that follow-up treatment with an oral antibiotic is&#xD;
      promising; but the non-inferiority and safety was not yet properly addressed. Neonatal switch&#xD;
      therapy, if proven to be safe and efficacious, would have a major impact on neonatal&#xD;
      well-being, mother-to-child bonding and moreover costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2017</start_date>
  <completion_date type="Actual">July 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter prospective randomized controlled non-inferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial re-infection within 28 days after cessation of antibiotic treatment (within 35 days after initial presentation)</measure>
    <time_frame>0-35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>0-35 days after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of re-admission</measure>
    <time_frame>0-35 days after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total costs and cost-effectiveness</measure>
    <time_frame>0-35 days after birth</time_frame>
    <description>Cost-effectiveness of intravenous to oral switch compared to a full course of antibiotics + possible extra costs due to early antibiotic switch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life between oral and intravenous antibiotic treatment</measure>
    <time_frame>0-35 days after birth</time_frame>
    <description>Two questionnaires on day 7 and 21 after admission, filled in by both parents. Data will be provided in a descriptive manner as no validated QoL questionnaires exist for neonates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above MIC (T&gt;MIC) of oral amoxicillin.</measure>
    <time_frame>0-7 days</time_frame>
    <description>2 blood samples after administration of antibiotic suspension at different time points will be taken.&#xD;
Time above MIC (T&gt;MIC) will be defined. Target MIC is 8 mg/liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above MIC (T&gt;MIC) of oral clavulanic acid.</measure>
    <time_frame>0-7 days</time_frame>
    <description>2 blood samples after administration of antibiotic suspension at different time points will be taken.&#xD;
Time above MIC (T&gt;MIC) will be defined. Target MIC is 8 mg/liter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Neonatal Infection</condition>
  <condition>Neonatal SEPSIS</condition>
  <arm_group>
    <arm_group_label>Oral group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.&#xD;
In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Clavulanate</intervention_name>
    <description>Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1</description>
    <arm_group_label>Oral group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Intravenous antibiotic therapy following local protocol</description>
    <arm_group_label>Intravenous group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neonates (≥ 35+0 weeks, 0-28 days old, ≥ 2 kg)&#xD;
&#xD;
          -  Probable bacterial infection defined as clinical symptoms and/or maternal risk factors&#xD;
             and elevated inflammatory markers for which empiric broad-spectrum antibiotic&#xD;
             treatment was initiated and needs to be continued for &gt; 48 hours&#xD;
&#xD;
          -  Clinically well&#xD;
&#xD;
          -  Toleration of oral feeding without overt vomiting&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Proven bloodstream infection&#xD;
&#xD;
          -  Absence of blood culture&#xD;
&#xD;
          -  Severe localized infection (meningitis, osteomyelitis, necrotizing enterocolitis)&#xD;
&#xD;
          -  Severe clinical sepsis (compromised circulation, need for mechanical ventilation)&#xD;
&#xD;
          -  Continuous need for a central venous line&#xD;
&#xD;
          -  Severe hyperbilirubinemia exceeding the exchange level&#xD;
&#xD;
          -  Parents inability to administer medication&#xD;
&#xD;
          -  Major congenital or syndromic anomalies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerdien Tramper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Franciscus Gasthuis &amp; Vlietland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meander Medical Center</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IJsselland Ziekenhuis</name>
      <address>
        <city>Capelle Aan Den IJssel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medical Center</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juliana Kinderziekenhuis-Haga Hospital</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC-Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscus Vlietland</name>
      <address>
        <city>Schiedam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.rainstudie.nl</url>
    <description>Study website (in dutch)</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Franciscus Gasthuis</investigator_affiliation>
    <investigator_full_name>Gerdien Tramper</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Antibiotic switch therapy</keyword>
  <keyword>Amoxicillin/clavulanic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available on request through a repository and shared after consent of the principal investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

